TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
16 Jan, 2020
Transcenta Holding’s (“Transcenta”) Chief Executive Officer Dr. Xueming Qian delivered a speech at the 38th Annual J.P. Morgan Healthcare Conference held in San Francisco, US yesterday. He shared with hundreds of invited guests and investors across the world Transcenta’s progress on key assets in the pipeline and the company’s future plans.
In his speech, Dr. Qian depicted Transcenta’s rapid growth since the merger and the company’s fully integrated capabilities on biologics discovery, process development, clinical development and manufacturing as well as senior management team experienced in innovative biologics development.
Dr. Qian also showed Transcenta’s remarkable progress made on the pipeline, in which MSB2311 was discovered and developed in-house as the world’s only PD-L1 antibody with pH-dependent binding property. This asset has shown potent anti-tumor activity and safety as well as tolerability profile in Phase I clinical trials with related data ready to be submitted to ASCO for later presentation. Another one is an antibody targeting Claudin18.2 (CLDN18.2) internally known as TST001. It has shown higher affinity and enhanced antibody-dependent cellular cytotoxicity (ADCC) activity in anti-tumor activity in vivo study. The investigational new drug (IND) of this asset has been filed with both NMPA and FDA. Additionally, the IND of an innovative PDL1-TGFβ bispecific antibody (internally known as TST005) and a transformative agent for bone disorders (internally known as TST002) in-licensed from Eli Lilly and Company is expected to be filed this year and the next.
Furthermore, he introduced Transcenta’s Process and Product Development and Manufacturing Facility (“Facility”) located in Hangzhou, China. The Facility has employed the first modular cleanroom of its kind in the country. All the cleanrooms stand over 2,000 square meters combined, capable of producing at significantly lower cost for partners. By applying Integrated Continuous Bioprocessing (ICB) platform, one 500L single use bioreactor (SUB) can produce 300-400kg of total drug substance per year, equal to four 2000L SUBs with fed-batch processes.
Lastly, Dr. Qian mentioned that Transcenta sealed a 100 million USD series B+ financing not long ago. The proceeds will be used to advance lead programs including the ones mentioned above. In the future, the company is planning to expand its pipeline and strengthen its team to prepare for IPO.
It was the first time for Transcenta to present in J.P. Morgan Healthcare Conference. Dr. Qian’s speech drew attention from all the guests and the milestones Transcenta has achieved in just one year after the merger gained recognition from numerous international investors and potential partners, who expressed interests in Transcenta and pursuing business opportunities.